Skin Basal Cell Carcinoma Clinical Trial
Official title:
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Facial Basal Cell Carcinomas
This clinical trial studies the effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery to remove skin lesions on the face. A margin is the area of normal tissue around a tumor taken out during surgery to make sure all of the cancer is removed. This clinical trial studies tissue samples to determine the least amount of tissue that must be removed to give an acceptable cure rate. This may allow less normal tissue to be removed from patients and may be a less expensive surgery.
PRIMARY OBJECTIVES:
I. To determine the success rate of narrow margin excisions of low-risk facial basal cell
carcinoma (BCC).
SECONDARY OBJECTIVES:
I. To determine the narrowest excision margin for low-risk facial BCC that gives an
acceptable (95%) cure rate over a 3 year follow-up period.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02978625 -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|
Phase 2 | |
Completed |
NCT02735356 -
Topical Itraconazole in Treating Patients With Basal Cell Cancer
|
Early Phase 1 | |
Completed |
NCT03180528 -
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
|
Phase 2 | |
Completed |
NCT02690948 -
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02699723 -
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
|
Early Phase 1 |